Ophthalmic devices coated with an active agent eluting coating are provided herein. Placement of the coated ophthalmic devices on the surface of eye results in modulation of cells responding to an immune modifying agent and reducing inflammation-related complications in the eye. Methods for treating ocular disorders are also provided herein. The disclosed subject matter is based, in part, on the discovery that ophthalmic devices coated with a cytokine eluting coating can shift early-stage macrophage polarization associated with alleviation of symptoms and causes of inflammatory ocular disorders.

A medical device including an internal wetting agent and a copolymer of a silicone monomer and satisfying the following conditions: (1) that the internal wetting agent contains a copolymer of an open-chain compound having an acidic group and an open-chain compound having an amide group; (2) that the internal wetting agent is contained in the range of from 0.1 to 10% by mass with respect to the whole medical device; and (3) that the copolymer of a silicone monomer has a hydroxyl group and that the content ratio of the hydroxyl group in the silicone monomer is in the range of from 0.0005 to 0.01 equivalents/g. A medical device containing an internal wetting agent and having excellent transparency and hydrophilicity can be obtained.

The invention provides methods of making microparticle and nanoparticle ocular implants from a compositions comprising: 99 to 60% (w/w) of a photopolymerizable composition selected from the group of fragments or monomers consisting of polyalkylene glycol diacrylate and polyalkylene glycol dimethacrylate, wherein the photopolymerizable composition has a molecular weight in the range of 100 to 20,000 Dalton; a biodegradable polymer selected from the group consisting of aliphatic polyester-based polyurethanes, polylactides, polycaprolactones, polyorthoesters and mixtures, copolymers, and block copolymers thereof; a photoinitiator; and a therapeutic agent.

This disclosure describes methods of preparing a decellularized Descemet's membrane and an isolated Descemet's membrane, methods of using an isolated Descemet's membrane, and tissues prepared using an isolated Descemet's membrane. This disclosure further describes a composition that includes an isolated Descemet's membrane. In some embodiments, the tissues and methods described herein may be used to treat a limbal stem cell deficiency or as an ocular surface bandage.

A crosslinkable composition comprises: A1) at least one multifunctional isocyanate-terminated urethane prepolymer comprising between 1 and 16 isocyanate functionalities on average, the prepolymer being a product of the reaction of a diisocyanate, a triisocyanate or a polyisocyanate with a functionality strictly greater than 3, with a polyol comprising 1 to 8 hydroxyl groups; and/or A2) at least one mono, di or polyisocyanate and/or an oligoglycerol; with B) at least one macropolyol chosen from: B1) oligoglycerols with an average degree of polymerisation less than or equal to 7, B2) glycerol dendrimers, B3) linear, branched or hyperbranched polyglycerols with a degree of polymerisation greater than or equal to 8, B4) mixtures of hyperbranched polyglycerols and linear, branched or hyperbranched oligoglycerols, with a degree of polymerisation of between 2 and 7, optionally functionalised.

An antimicrobial polymer for use in contact lenses includes at least one antimicrobial monomer; and at least one other monomer selected from an acrylic monomer, a hydrophobic acrylic monomer, a hydrophilic acrylic monomer, a vinyl monomer and/or a collagen monomer.

The present invention resides in a method for producing jellyfish collagen hydrogels and kits for producing the same. The jellyfish collagen hydrogels can be used in the culture of cells. According to the invention, there is a process for producing jellyfish collagen hydrogels comprising jellyfish collagen fibrils, said process comprising the steps of: mixing a solution of purified jellyfish collagen and an aqueous neutralisation buffer; and incubating the mixture for a sufficient time to enable jellyfish collagen fibrils to form, wherein a cross-linking agent is either added during to mixing step or during or after the incubation of the mixture.

The present invention provides a method for producing a retinal cell or a retinal tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells in a medium containing 1) a TGFβ family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension in a medium containing a Wnt signal transduction pathway inhibiting substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a Wnt signal transduction pathway inhibiting substance in a medium containing a BMP signal transduction pathway activating substance to obtain an aggregate containing a retinal cell or a retinal tissue.

The present disclosure relates to biocompatible injectable compositions. The provided compositions comprise or consist of silk fibroin, hyaluronic acid, horseradish peroxidase, hydrogen peroxide, and water. The injectable composition is tunable and may be adapted to have a gelation time from 3 minutes to 20 minutes, a storage modulus of 6 Pa to 4000 Pa, be injectable through a needle having a size from 32 G to 18 G, have optical transmittance from 75% to 95% for at least one wavelength from 400 nm to 700 nm, have a volume expansion from 5% to 400% relative to an original volume of the hydrogel after soaking in an aqueous solution for 12 hours, and/or have a hydrogel stability by maintaining at least 75% of the storage modulus and the optical transmittance of the hydrogel after 6 months in vivo. The present disclosure provides methods for making and using the same.

Intraocular implants and methods of forming intraocular implants are described herein. The intraocular implant can include a powered optic and a lens holder. The optic can be mechanically coupled to an inner periphery of the lens holder to form the intraocular implant. A portion of the lens holder can include a mask disposed about the optic to increase depth of focus in a human patient.